Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Psoriasis concept on skin of color | Image credit: CandyRetriever - stock.adobe.com
VISIBLE Trial Advances Diversity in Psoriasis Research

December 11th 2024

Novel strategies in the VISIBLE trial set a new standard for recruiting and retaining diverse participants with skin of color in dermatology clinical trials.

Psoriasis | image credit: pimentos – stock.adobe.com
Patients With Higher Disease Burden, Lower HRQoL More Likely to Switch to Biologic Therapies

December 10th 2024

Plaque psoriasis | Image credit: ksu_ok - stock.adobe.com
Most Patients With Moderate to Severe Psoriasis Continue Secukinumab Treatment

December 4th 2024

Cleansing vessels and veins from cholesterol. | Image credit: Kudryavtsev - stock.adobe.com
Psoriasis Risk Linked to Elevated Non-HDL to HDL Cholesterol Ratio, Study Finds

November 19th 2024

Image credit: Nitr - stock.adobe.com
Dried Fruit Intake Linked to Benefits in Psoriasis Treatment

November 12th 2024

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
December 13th 2024

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
December 13th 2024

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Patient Adherence With Psoriasis Treatments
December 13th 2021

Patient Adherence With Psoriasis Treatments

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, explain the difficulties of patient adherence to psoriasis treatments.
Disease Burden for Patients With Plaque Psoriasis
December 13th 2021

Disease Burden for Patients With Plaque Psoriasis

Dr Mark Lebwohl explains disease burden for patients with plaque psoriasis and discusses the common comorbidities clinicians see.
Physician with patient.
December 9th 2021

Nail Involvement May Reduce Efficacy of Ustekinumab For Psoriasis

Matthew Gavidia
Nail involvement was shown to reduce the effectiveness of ustekinumab in the treatment of moderate to severe psoriasis, whereas secukinumab exhibited overall higher efficacy than ustekinumab and similar response rates regardless of nail involvement.
Person clasping hand.
December 6th 2021

Patients With Psoriatic Disease May Have Greater Risk of VTE, PVD

Matthew Gavidia
Patients with psoriasis were found to have a more than 20% increased risk of developing incident venous thromboembolism (VTE) and peripheral vascular disease (PVD), with notable at-risk groups including women and those with concomitant psoriatic arthritis.
Person touching neck.
December 2nd 2021

Brodalumab Improves Skin Clearance, QOL vs Ustekinumab in Comorbid Psoriasis, PsA

Matthew Gavidia
Patients with concomitant psoriasis and psoriatic arthritis (PsA) were shown to be 3.1-fold more likely to achieve complete skin clearance when treated with brodalumab vs ustekinumab after 52 weeks, with further improvements reported for quality of life (QOL).
Physician and patient.
November 29th 2021

TNF Inhibitors Show Real-world Efficacy on QOL of Patients With Nail Psoriasis, PsA

Matthew Gavidia
Patients with concomitant psoriasis, nail psoriasis, and psoriatic arthritis (PsA) exhibited significant improvements in joint and disease severity symptoms, as well as quality of life (QOL) after 3 months of treatment with tumor necrosis factor-α (TNF) inhibitors of adalimumab, etanercept, or infliximab.
Magnifying risk in one person of a group.
November 26th 2021

Assessing Risk Factors for PsA Development in Patients With Psoriasis

Matthew Gavidia
Use of biologics and age may influence risk of psoriatic arthritis (PsA) development in patients with psoriasis, according to findings presented at the 2021 American College of Rheumatology Annual Meeting.
Health care cost.
November 20th 2021

Greater Work Impairment, Comorbidity Burden Linked With Concomitant Psoriasis, PsA

Matthew Gavidia
Findings presented at the 2021 American College of Rheumatology Annual Meeting showed that patients with concomitant psoriasis and psoriatic arthritis (PsA) reported greater incidence of obesity, hypertension, and diabetes, as well as a higher likelihood of work inability than those with only psoriasis.
Elderly person's hands.
November 17th 2021

Guselkumab Linked With Long-term Improvement of Joint Manifestations, Disease Activity in PsA

Matthew Gavidia
Phase 3 findings of the DISCOVER-2 trial presented at the 2021 American College of Rheumatology Annual Meeting indicated that guselkumab (Tremfya) provided long-term improvement in joint manifestations, disease activity, and physical function among patients with psoriatic arthritis who had no prior biologic treatment.
Pill bottle.
November 12th 2021

Prior Biologic Use, Body Weight May Impact Guselkumab Efficacy in Psoriasis

Matthew Gavidia
Real-world patients with moderate-to-severe psoriasis were shown to exhibit impaired efficacy with guselkumab treatment if they had history of prior biologic use, particularly anti-interleukin (IL)-17 exposure, with heavier patients linked with delayed onset of therapeutic response.
Psoriasis on hand.
November 9th 2021

Real-world Findings Show Apremilast Effective Long Term in Plaque Psoriasis

Matthew Gavidia
Findings of a real-world, single-center study indicated that apremilast was effective and safe long-term in the treatment of moderate-to-severe plaque psoriasis.
Arthritis pain in hands.
November 3rd 2021

Ixekizumab Linked With Improved Outcomes vs Adalimumab in PsA With Concomitant Psoriasis

Matthew Gavidia
A greater proportion of biologic-naive patients with psoriatic arthritis treated with ixekizumab vs adalimumab achieved the combined endpoint of 100% resolution in the Psoriasis Area Severity Index and 50% or greater improvement in the American College of Rheumatology criteria at week 24 and 52.
Site Logo
November 1st 2021

Economic Burden of Joint Disease in Psoriasis: US Claims Analysis

Patricia Prince, MPH Michelle Skornicki, MPH Robert Suruki, ScD Edward Lee, PharmD Anthony Louder, PhD
This retrospective claims analysis found that concomitant joint disease in psoriasis is associated with greater health care resource utilization and health care costs than psoriasis alone.
Arrow of people.
October 29th 2021

Biologic Treatment, Smoking May Increase Psoriasis Risk in Patients With IBD

Matthew Gavidia
Patients with inflammatory bowel disease (IBD) treated with adalimumab had greater risk of developing psoriasis than those administered infliximab, with gender and smoking incidence also linked with greater IBD risk.
Physician evaluating pill bottle.
October 26th 2021

Biologic, Antirheumatic Drug Use May Increase Risk of Adverse Pregnancy Outcomes in Women With Psoriasis

Matthew Gavidia
Pregnant women with psoriasis were found to be at increased risk of experiencing preterm birth and Cesarean delivery, with patients undergoing anti-rheumatic treatment during their first pregnancy indicated to be at significantly greater risk.
AMCP Studies Highlight Workplace Costs of Skin Care
October 21st 2021

AMCP Studies Highlight Workplace Costs of Skin Care

Tony Hagen
Studies presented at Academy of Managed Care Pharmacy Nexus 2021 elucidated costs of skin treatment for workers in terms of recovery time taken and percentage of salary.
Health charts.
October 20th 2021

Ixekizumab Improves Retention vs Secukinumab in Patients With Psoriasis

Matthew Gavidia
Biologic-experienced patients with psoriasis exhibited significantly improved treatment adherence and lower discontinuation, nonpersistence, and switching rates over 18 months when prescribed ixekizumab vs secukinumab.
Frustrated young adult.
October 15th 2021

Evaluating Treatment Goals, Preferences in Parents and Young Patients With Psoriasis

Matthew Gavidia
Pediatric populations, young adults, and parents all identified differing goals and preferences of treatment for psoriasis, with the most important treatment goals overall cited as lesion prevention and reduction.
Person scratching neck.
October 13th 2021

Novel Calcipotriene, Betamethasone Dipropionate Cream Linked With Improved Outcomes and QOL in Psoriasis

Matthew Gavidia
A novel formulation of calcipotriene (CAL), betamethasone dipropionate (BDP) cream was found to be more effective, provide superior quality of life, and safe in patients with psoriasis, compared with standard CAL/BDP topical suspension/gel.
Physician speaking with patient.
October 9th 2021

Evaluating Common Conditions That Precede Psoriatic Arthritis Diagnosis

Matthew Gavidia
Patients with psoriatic arthritis (PsA) were found to be more likely to report musculoskeletal symptoms and dermatologic issues prior to initial PsA diagnosis.
Physician checking patient's hand.
October 6th 2021

Brodalumab May Enhance Skin Clearance, QOL vs Ustekinumab for Psoriasis

Matthew Gavidia
Patients with moderate to severe psoriasis were shown to achieve and maintain higher levels of complete skin clearance and quality of life when treated with brodalumab vs ustekinumab, regardless of the presence of lifestyle risk factors.
Patient and physician.
October 1st 2021

High Rate of Secukinumab Retention Shown Long Term in Patients With Psoriasis

Matthew Gavidia
Secukinumab was associated with a high rate of short- and long-term drug survival in the treatment of patients with psoriasis, with factors such as obesity and prior biologic use linked to discontinuation of use.
Physician and patient.
September 29th 2021

Positive Fecal Immunochemistry Test May Increase Risk of Psoriasis

Matthew Gavidia
Patients with a positive fecal immunochemistry test (FIT) were shown to be at significantly greater risk of developing psoriasis than those with FIT-negative tests.
Person smoking a cigarette.
September 25th 2021

Smoking, Periodontitis Linked With Increased Risk of Psoriasis

Matthew Gavidia
Patients with periodontitis had a potential increased risk of developing psoriasis, particularly those who smoked.
Measurement tapes.
September 22nd 2021

Body Surface Area May Predict Risk of Psoriatic Arthritis in Patients With Psoriasis

Matthew Gavidia
Greater body surface area was shown to correlate with an increased risk of psoriatic arthritis development in patients with psoriasis, with obesity and depression also identified as risk factors.
Person touching skin on their back.
September 18th 2021

Guselkumab Associated With Improved HRQOL, Skin Manifestations in Patients With Psoriasis

Matthew Gavidia
Treatment of guselkumab was found to be safe and effective in improving health-related quality-of-life (HRQOL) and skin manifestations of patients with moderate to severe psoriasis in a real-world setting.
Stethoscope on dollar bills (health care cost).
September 15th 2021

High OOP Costs for Treatment of Psoriatic Disease Found in Medicare Beneficiaries

Matthew Gavidia
Medicare beneficiaries with psoriasis and psoriatic arthritis were found to pay high annual out-of-pocket (OOP) costs for treatment, which researchers attributed to rising drug prices and reliance on co-insurance for patient cost-sharing.
Diabetes stock photo.
September 11th 2021

Alpha-Glucosidase Inhibitor Use in Type 2 Diabetes Linked With Increased Psoriatic Disease Risk

Matthew Gavidia
Discontinued use and high dosage of alpha-glucosidase inhibitors in combination with metformin was shown to increase risk of psoriasis and psoriatic arthritis in patients with type 2 diabetes compared with those given only metformin.
Physician checking joint swelling of patient.
September 9th 2021

Phase 2 Study Finds Tildrakizumab Effective for PsA Manifestations

Matthew Gavidia
Findings of a phase 2b study indicated that use of tildrakizumab was associated with significant improvements in joint and skin manifestations of patients with psoriatic arthritis (PsA), although improvement in symptoms of dactylitis and enthesitis were not observed.
Computer graphic of body and medication
September 1st 2021

Depression, Lack of Efficacy Linked With DMARD Discontinuation in PsA

Jared Kaltwasser
By year 5 of therapy with disease-modifying anti-rheumatic drugs (DMARDs), only about one-third of patients with psoriatic arthritis (PsA) were expected to be continuing with their therapy.
<1
...
456789101112
...
14>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo